Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=189 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Phase 2 N=87 Naltrexone for Individuals of East Asian Descent
Alcohol Use Disorder
Primary: Subjective Response - Craving for Alcohol — 1.7037; 1.9965; 2.1012; 1.8478 score on a scale — p=0.39
Phase 2 N=11 Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
Plasma Cell Myeloma
Primary: Proportion of Complete Response Plus Very Good Partial Response (VGPR) — 0 proportion of participants
Phase 3 N=68 Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Pantothenate Kinase-Associated Neurodegeneration
Primary: Number of Participants With Adverse Events — 22; 42; 12; 14 Participants
N/A N=579 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets
Osteoporosis
Primary: Cumulative Percentage of Participants With New or Worsening Vertebral Body Fractures — 5.43; 7.35; 7.80; 8.82 Percentage of Participants
Phase 1 N=30 OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
Chronic Pain
Primary: AUC0-48hr of Noroxycodone Plasma Concentration. — 81.72; 325.51 hr*ng/mL
N/A N=20 Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Short Laryngologic Surgery
Laryngologic Surgical Procedures
Primary: Average Oxygen Saturation by Pulse Oximetry (SpO2) (Primary Anesthesia Outcome) — 93; 98.7 percentage of saturation (SpO2) — p=0.006
N/A N=53 Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Ischemic Stroke
Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants
Phase 2 N=121 Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)…
Phase 2 N=16 Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
Pulmonary Cystic Fibrosis
Primary: Cohorts 1 and 2: Safety Assessments, Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). — 0; 0; 0; 0 Participants
Phase 3 N=924 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
Rosacea
Primary: Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12 — -64.28; -65.15; -57.84 percent change — p=<.0001
Phase 3 N=422 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
Actinic Keratosis
Primary: Percentage of Participants With Treatment Success (Complete Clearance) at Week 6 — 33.9; 33.9; 3.3 percentage of participants — p=<0.0001
Phase 2 N=148 Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859
N/A N=797 Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)
Peripheral Arterial Disease · Quality of Life · Quality of Care
Primary: Peripheral Artery Disease (PAD) - Specific Health Status — 70.7; 66.9 units on a scale of 0-100